Progression, Survival
Conditions
Keywords
osteosarcoma, refractory to chemotherapy, unresectable, PD-L1, VENTANA PD-L1 (SP263)
Brief summary
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.
Interventions
OTHERall study participants
patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* diagnosis confirmed histologically and reviewed centrally; * received surgery in Musculoskeletal Tumor Center of Peking University People's Hospital with appropriate sample for immunohistochemical staining; * progressing upon prior treatment (completed \>4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (PD); * having measurable lesion according to RECIST 1.1; * Eastern Cooperative Oncology Group performance status 0-1 with a life expectancy \>3 months; * intend to receive anti-PD-1/anti-PD-L1 antibody for therapy.
Exclusion criteria
* fail to be followed up regularly. * sample disqualification.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PD-L1 expression level | 2 months | all those specimens will be tested for expression level,Tumors with ≥50% cells showing positive membrane staining were considered to have high expression of PD-L1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | 2 years | from the timing of testing to disease progression/death whichever comes first |
| overall survival | 5 years | from the timing of testing to death/last follow-up |
Countries
China
Contacts
Primary ContactLu Xie, M.D.
Backup ContactJie Xu, M.D.
Outcome results
None listed